| Literature DB >> 33807001 |
Raquel Bandeira da Silva1, Mauro José Salles2,3.
Abstract
Gram-negative bacteria (GNB), including multidrug-resistant (MDR) pathogens, are gaining importance in the aetiology of prosthetic joint infection (PJI). This retrospective observational study identified independent risk factors (RFs) associated with MDR-GNB PJI and their influence on treatment outcomes. We assessed MDR bacteria causing hip and knee PJIs diagnosed at a Brazilian tertiary hospital from January 2014 to July 2018. RFs associated with MDR-GNB PJI were estimated by bivariate and multivariate analyses using prevalence ratios (PRs) with significance at p < 0.05. Kaplan-Meier analysis was performed to evaluate treatment outcomes. Overall, 98 PJI patients were analysed, including 56 with MDR-GNB and 42 with other bacteria. Independent RFs associated with MDR-GNB PJI were revision arthroplasty (p = 0.002), postoperative hematoma (p < 0.001), previous orthopaedic infection (p = 0.002) and early infection (p = 0.001). Extensively drug-resistant GNB (p = 0.044) and comorbidities (p = 0.044) were independently associated with MDR-GNB PJI treatment failure. In sum, MDR-GNB PJI was independently associated with previous orthopaedic surgery, postoperative local complications and pre-existing infections and was possibly related to selective pressure on bacterial skin colonisation by antibiotics prescribed for early PJI. Infections due to MDR-GNB and comorbidities were associated with higher treatment failure rates.Entities:
Keywords: epidemiology; extensively drug-resistant; hematoma; multidrug-resistant Gram-negative bacteria; prosthetic joint infection; risk factors; surgical site infection
Year: 2021 PMID: 33807001 PMCID: PMC8004651 DOI: 10.3390/antibiotics10030340
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Demographics and clinical characteristics of the study population.
| Characteristics | Number of Patients |
|---|---|
| Age (years) (mean ± S.D.) | 67.3 ± 13.2 |
| P50 (P25–P75) | 69.5 (58.7–77) |
| Age group | |
| up to 50 | 10 (1.2) |
| 51–60 | 23 (23.5) |
| 61–70 | 20 (20.4) |
| 71–80 | 31 (31.6) |
| over 80 | 14 (14.3) |
| Time between prosthesis and diagnosis (days) P50 (P25–P 75) | 32 (20–242) |
|
| |
| Comorbidities (yes) | 71 (72.4) |
| SAH a | 60 (61.2) |
| DM b | 20 (20.4) |
| Malnutrition | 8 (8.2) |
| Anemia | 2 (2.0) |
| Neoplasm | 1 (1.0) |
| Lung disease | 5 (5.1) |
| Metabolic syndrome | 18 (18.4) |
| Cardiovascular disease | 5 (5.1) |
| Other comorbidities c | 11 (11.3) |
| Previous use of an antimicrobial | 37 (37.8) |
|
| |
| Arthroplasty | |
| Total | 75 (76.5) |
| Primary | 56 (57.2) |
| Elective | 59 (60.2) |
| Hip | 82 (83.7) |
| DAIR d | 69 (70.4) |
| Procedure duration greater than 2.5 h | 5 (5.1) |
| Blood transfusion | 16 (16.3) |
|
| |
| Concomitant non-orthopedic infection | 11 (11.2) |
| Previous ortopedic infection | 19 (19.4) |
| Early infection | 68 (69.4) |
| Sepsis | 2 (2.0) |
SAH a: Systemic arterial hypertension; DM b: Diabetes Mellitus; Other comorbidities c: rheumatoid arthritis, hypothyroidism, hyperthyroidism, depression. DAIR d: debridement and implant retention.
Description of 104 microorganisms isolated from bone and soft tissue cultures of patients with PJI described in the study.
|
|
|
|
| 31 (51.7) |
|
| 8 (13.3) |
|
| 6 (10.0) |
|
| 5 (8.3) |
|
| 4 (6.7) |
|
| 3 (5.0) |
| Others GNB-MDR | 3 (5.0) |
|
|
|
| MSSA c | 16 (36.4) |
|
| 6 (13.6) |
| MRSA d | 5 (11.4) |
|
| 4 (9.1) |
|
| 3 (6.8) |
|
| 2 (4.5) |
|
| 2 (4.5) |
|
| 2 (4.5) |
|
| 1 (2.3) |
|
| 1 (2.3) |
|
| 1 (2.3) |
|
| 1 (2.3) |
MDR/XDR GNB a: Multidrug resistant/extensively drug-resistant, gram-negative bacteria; PJI b; prosthetic joint infection; MSSA c; Methicillin-sensitive Staphylococcus aureus, MRSA d; Methicillin-resistant Staphylococcus aureus.
Evaluation the influence of variables of interest on the outcome of PJI caused by MDR- GNB compared to other bacteria–univariate analysis.
| Variables | PJI a | ||
|---|---|---|---|
| MDR/XDR GNB b | Other Bacteria | ||
| No. (%) | No. (%) | ||
| N = 56 | N = 42 | ||
|
| |||
| Males | 29 (70.7) | 12 (29.3) | 0.021 * |
| Females | 27 (47.4) | 30 (52.6) | |
| Age (years) | F | ||
| Mean ± Standard deviation | 68.2 ± 13.8 | 66.0 ± 1.4 | 0.415 *** |
| Age group | |||
| up to 50 | 7 (70.0) | 3 (30.0) | 0.126 ** |
| 51–60 years | 13 (56.5) | 10 (43.5) | |
| 61–70 years | 7 (35.0) | 13 (65.0) | |
| 71–80 years | 18 (58.1) | 13 (41.9) | |
| above 80 years | 11 (78.6) | 3 (21.4) | |
|
| |||
| Presence of comorbidities | 41 (73.2) | 30 (71.4) | 0.845 * |
| SAH d | 33 (58.9) | 27 (64.3) | 0.590 * |
| DM e | 12 (21.4) | 8 (19.0) | 0.772 * |
| Malnutrition | 7 (12.5) | 1 (2.4) | 0.133 ** |
| Anemia | 2 (3.6) | 0 (0) | 0.505 ** |
| Neoplasm | 0 (0) | 1 (2.4) | 0.429 ** |
| Lung disease | 0 (0) | 5 (9) | 0.013 ** |
| Metabolic syndrome | 6 (10.7) | 12 (28.6) | 0.024 * |
| Cardiovascular disease | 4 (7.1) | 1 (2.4) | 0.388 ** |
| Other comorbidities f | 4 (7.1) | 7 (16.7) | 0.197 ** |
| Alcoholism | 12 (21.4) | 2 (4.8) | 0.020 * |
| Smoking | 9 (16.1) | 4 (9.5) | 0.344 * |
| ASA classification g | |||
| 1 | 8 (14.3) | 13 (31.0) | 0.114 * |
| 2 | 28 (50.0) | 19 (45.2) | |
| 3 or 4 | 20 (35.7) | 10 (23.8) | |
| Previous orthopedic infection | 20 (35.7) | 0 (0) | 0.000 * |
|
| |||
| Yes | 31 (55.4) | 6 (14.3) | 0.000 * |
| Quinolones | 12 (21.4) | 3 (7.1) | 0.052 * |
| β-Lactam Antibiotics | 20 (35.7) | 4 (9.5) | 0.003 * |
| Antimicrobial combination | 10 (17.9) | 1 (2.4) | 0.000 ** |
|
| |||
| Arthroplasty | |||
| Total | 41 (73.2) | 34 (81.0) | 0.371 * |
| Revision | 66.1 (37) | 11.9 (5) | 0.000 * |
| Non-elective | 31 (55.4) | 8 (19.0) | 0.000 * |
| Hip | 56 (100) | 26 (61.9) | 0.000 * |
| Duration of the procedure > 2.5 h | 8 (14.3) | 7 (16.7) | 0.746 * |
| Blood transfusion | 16 (28.6) | 3 (7.1) | 0.008 * |
|
| |||
| Concomitant non-orthopedic infection | 11 (19.6) | 2 (4.8) | 0.032 * |
| Previous orthopedic infection | 20 (35.7) | 0 (0) | 0.000 * |
| Polymicrobial infection | 4 (7.1) | 4 (9.5) | 0.721 ** |
| Early infection | 32 (57.1) | 37 (88.1) | 0.001 * |
| Postoperative hematoma | 29 (51.8) | 1 (2.4) | 0.000 * |
| Sepsis associated with infection | 2 (3.6) | 0 (0) | 0.505 ** |
PJI a: Prosthetic Joints Infections; MDR/XDR GNB b: Multidrug resistant/extensively drug-resistant, gram-negative bacteria; c p-values : <0.05 were considered statistically significant; SAH d: Systemic arterial hypertension; DM e: diabetes Mellitus; Other comorbidities f: rheumatoid arthritis, hypothyroidism, hyperthyroidism, depression; ASA g: American Anesthesiology Association. Significance probabilities refer to the Chi-squared test (*), Fisher’s exact test (**), and Student’s t-test (***).
Predisposing factors independently associated with MDR-GNB a PJI b in the multivariate analysis.
| Variables | Prevalence Ratio 95% CI | |
|---|---|---|
| Revision arthroplasty | 1.7 (1.2; 2.4) | 0.002 |
| Previous orthopedic infection | 1.5 (1.1; 2.1) | 0.020 |
| Postoperative hematoma | 2.6 (1.7; 4.0) | <0.001 |
| Early infection | 2.2 (1.4; 3.5) | 0.001 |
MDR-GNB a: Multidrug resistant gram-negative bacteria; PJI b; prosthetic joint infection; p-values c < 0.05 were considered statistically significant.
Comparative analysis between the two study groups regarding the time elapsed between prosthesis and diagnosis and time to therapeutic failure.
| Variable | PJI by MDR-GNB | Descriptive Measures | |||
|---|---|---|---|---|---|
| Min-Max | Median | Mean ± SD | |||
| Time elapsed between prosthesis and diagnosis (days) | Yes | 7.0–5.040.0 | 37.0 (20.3–472.5) | 453.1 ± 934.7 | 0.066 |
| No | 7.0–1.825.0 | 30.0 (20.0–39.3) | 95.4 ± 285.4 | ||
| Time to failure (days) | Yes | 1.0–179.0 | 68.0 (37.0–102.3) | 77.1 ± 50.1 | 0.063 |
| No | 34.0–225.0 | 105.0 (72.0–181.0) | 119.1 ± 62.9 | ||
* Significance probability refers to the Mann-Whitney test.
Evaluation of the influence of variables of interest on the time to therapeutic failure–univariate and multivariate analysis.
| Variables | Univariate Analysis | Prevalence Ratio | |
|---|---|---|---|
| PJI b by GNB c | 0.087 | - | - |
| PJI by MDR-GNB d | 1.0 (0.4; 2.5) | 0.991 | |
| PJI by XDR-GNB e | 2.3 (1.0; 5.2) | 0.044 | |
| DAIR f surgical strategy | 0.842 | - | - |
| Presence of comorbidities | 0.038 | 2.9 (1.0; 8.4) | 0.044 |
p-values a < 0.05 were considered statistically significant. PJI b: Prosthetic Joints Infections; GNB c: Gram-negative bacteria; MDR-GNB d: multidrug-resistant, gram-negative bacteria; XDR-GNB e: extensively-resistant, gram-negative bacteria; DAIR f: debridement and implant retention. Significance probabilities in the univariate analysis refer to Log-Rank test. Significance probabilities in the multivariate analysis refer to Cox regression.
Figure 1Kaplan–Meier survival curve for treatment failure (death/recurrence) considering PJIs caused by XDR-GNB and other bacteria.
Figure 2Kaplan–Meier survival curve for treatment failure (death/recurrence) among PJI patients with and without comorbidities.